Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Copegus® Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

NCT01687270
View directory record Official record
Conditions
Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
Interventions
Sofosbuvir, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
San Francisco, California • Indianapolis, Indiana • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PSI-7977, Daclatasvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Coronado, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

NCT01853254
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

NCT00545233
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

NCT00088504
View directory record Official record
Conditions
Hepatitis C, Hepatitis
Interventions
Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
67
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

NCT01471574
View directory record Official record
Conditions
Hepatitis C, Genotype 1
Interventions
Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Withdrawn Phase 2 Interventional

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

NCT01629732
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, BMS-986094, Ribavirin, Placebo for BMS-986094
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01309932
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV)
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

NCT01938430
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
25
States / cities
Bakersfield, California • Pasadena, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00743795
View directory record Official record
Conditions
HCV Infection
Interventions
placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
48
States / cities
Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

NCT02201953
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 25, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

NCT02600351
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
38
States / cities
Little Rock, Arkansas • Los Angeles, California • Pasadena, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

NCT01581138
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
VX-222, telaprevir, ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

NCT02094443
View directory record Official record
Conditions
Hepatitis C, Liver Disease
Interventions
Alisporivir, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Bakersfield, California • Lancaster, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

NCT01428063
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Daclatasvir, Asunaprevir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

NCT01984294
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV, GS-9669
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2018 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

NCT00623428
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • Lancaster, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

NCT00800735
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Pegylated-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • Lutherville, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Sofosbuvir, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

NCT01718158
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Daclatasvir, Telaprevir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Long Beach, California • Marietta, Georgia • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 25, 2026, 5:30 PM EDT
Terminated Phase 4 Interventional Results available

Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

NCT01592006
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon alfa-2a, Ribavirin, telaprevir
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

NCT01973049
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Asunaprevir, BMS-791325, Ribavirin, Placebo matching Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 25, 2026, 5:30 PM EDT